Asymmetric dimethylarginine concentration and recurrence of atrial tachyarrythmias after catheter ablation in patients with persistent atrial fibrillation

Journal of Interventional Cardiac Electrophysiology

Volumn 32, Issue 2, 2011, Pages 147-154

  Yang, Li ^a   Xiufen, Qu ^a   Shuqin, Sun ^a   Yang, Yu ^a   Ying, Song ^a   Yanwei, Yu ^a   Wei, Feng ^a   Dechun, Yin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine; Atrial; Atrial fibrillation; Catheter ablation; Recurrence

Indexed keywords

DIMETHYLARGININASE;

ADULT; ARTICLE; CATHETER ABLATION; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; SUPRAVENTRICULAR TACHYCARDIA;

ARGININE; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BODY SURFACE POTENTIAL MAPPING; CATHETER ABLATION; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855658119     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-011-9588-7     Document Type: Article

References (45)

1. Calkins, H., Brugada, J., Packer, D. L., Cappato, R., Chen, S. A., Crijns, H. J., et al. (2007). HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. Heart Rhythm, 4, 816-861.
2. Weerasooriya, R., Khairy, P., Litalien, J., Macle, L., Hocini, M., Sacher, F., et al. (2011). Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? Journal of the American College of Cardiology, 57(2), 160-166.
3. Allessie, M., Ausma, J., & Schotten, U. (2002). Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovascular Research, 54(2), 230-246. (Pubitemid 34327903)
4. Frustaci, A., Chimenti, C., Bellocci, F., Morgante, E., Russo, M. A., & Maseri, A. (1997). Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 96, 1180-1184. (Pubitemid 27344221)
5. Liu, H., Xiufen, Qu, Liang, Z., Chen, W., Xia, W., & Song, Y. (2008). Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs. Biochemical and Biophysical Research Communications, 377, 884-888.
6. Xia, W., Qu, X., Yu, Y., Zhang, X., Feng, W., & Song, Y. (2008). Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion. Pacing and Clinical Electrophysiology, 31, 1036-1040.
7. Maldonado, G., & Greenland, S. (1993). Simulation study of confounder-selection strategies. American Journal of Epidemiology, 138(11), 923-936. (Pubitemid 24002359)
8. Vallance, P., Leone, A., Calver, A., Collier, J., & Moncada, S. (1992). Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet, 339, 572-575.
9. De Gennaro Colonna, V., Bianchi, M., Pascale, V., Ferrario, P., Morelli, F., Pascale, W., et al. (2009). Asymmetric dimethylarginine (ADMA) : an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Medical Science Monitor, 15(4), RA91-RA101.
10. Cengel, A., Sahinarslan, A., Biberoǧlu, G., Hasanoǧlu, A., Tavil, Y., Tulmaç, M., et al. (2008). Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiologica, 63(1), 33-37. (Pubitemid 351262964)
11. Lehto, M., Jurkko, R., Parikka, H., Mäntynen, V., Väänänen, H., Montonen, J., et al. (2009). Reversal of atrial remodeling after cardioversion of persistent atrial fibrillation measured with magnetocardiography. Pacing and Clinical Electrophysiology, 32(2), 217-223.
12. Novo, G., Guttilla, D., Fazio, G., Cooper, D., & Novo, S. (2009). The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. British Journal of Clinical Pharmacology, 66(3), 345-351.
13. Li, J., Solus, J., Chen, Q., Rho, Y. H., Milne, G., Stein, C. M., et al. (2010). Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm, 7(4), 438-444.
14. Van Wagoner, D. R. (2008). Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. Journal of Cardiovascular Pharmacology, 52(4), 306-313.
15. Van Gelder, I. C., Crijns, H. J., Van Gilst, W. H., Verwer, R., & Lie, K. I. (1991). Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. The American Journal of Cardiology, 68(1), 41-46.
16. Berruezo, A., Tamborero, D., Mont, L., Benito, B., Tolosana, J. M., Sitges, M., et al. (2007). Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. European Heart Journal, 28(7), 836-841. (Pubitemid 47343599)
17. Skalidis, E. I., Zacharis, E. A., Tsetis, D. K., Pagonidis, K., Chlouverakis, G., Yarmenitis, S., et al. (2007). Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. The American Journal of Cardiology, 1, 99(9), 1258-1262. (Pubitemid 46659865)
18. Aldhoon, B., Melenovský, V., Peichl, P., & Kautzner, J. (2010). New insights into mechanisms of atrial fibrillation. Physiological Research, 59(1), 1-12.
19. Kourliouros, A., Savelieva, I., Kiotsekoglou, A., Jahangiri, M., & Camm, J. (2009). Current concepts in the pathogenesis of atrial fibrillation. American Heart Journal, 157(2), 243-252.
20. Yamada, T., Murakami, Y., Okada, T., Yoshida, N., Toyama, J., Yoshida, Y., et al. (2007). Plasma brain natriuretic peptide level after radiofrequency catheter ablation of paroxysmal, persistent, and permanent atrial fibrillation. Europace, 9, 770-774. (Pubitemid 47371652)
21. Kallergis, E. M., Manios, E. G., Kanoupakis, E. M., Mavrakis, H. E., Kolyvaki, S. G., Lyrarakis, G. M., et al. (2008). The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart, 94(2), 133-134.
22. Trocha, M., Szuba, A., Merwid-Lad, A., & Sozanski, T. (2010). Effect of selected drugs on plasma asymmetric dimethylarginine (ADMA) levels. Die Pharmazie, 65(8), 562-571.
23. Schneider, M. P., Hua, T. A., Böhm, M., Wachtell, K., Kjeldsen, S. E., & Schmieder, R. E. (2010). Prevention of atrial fibrillation by renin-angiotensin system inhibition a metaanalysis. Journal of the American College of Cardiology, 55(21), 2299-2307.
24. Xia, W., Yin, Z., Li, J., Song, Y., & Qu, X. (2009). Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing and Clinical Electrophysiology, 32(12), 1562-1566.
25. Lai, J., Zhou, D., Xia, S., Shang, Y., Want, L., Zheng, L., et al. (2009). Reduced testosterone levels in males with lone atrial fibrillation. Clinical Cardiology, 32(1), 43-46.
26. Korantzopoulos, P., Kolettis, T. M., Kountouris, E., Dimitroula, V., Karanikis, P., Pappa, E., et al. (2005). Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. International Journal of Cardiology, 10, 102(2), 321-326. (Pubitemid 40854050)
27. Kubes, P., & Suzukim, G. D. N. (1991). Nitric oxide: an endogenous modulator of leukocyte adhesion. Proceedings of the National Academy of Sciences, 88, 4651-4655. (Pubitemid 21914599)
28. Sarkar, R., Meinberg, E. G., Stanley, J. C., Gordon, D., & Webb, R. C. (1996). Nitric oxide reversibly inhibits themigration of cultured vascular smooth muscle cells. Circulation Research, 78, 225-230. (Pubitemid 26042839)
29. Feng, Q., Song, W., Lu, X., Hamilton, J. A., Lei, M., Peng, T., et al. (2002). Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation, 106, 873-879.
30. Van Wagoner, D. R. (2003). Electrophysiological remodeling in human atrial fibrillation. Pacing and Clinical Electrophysiology, 26, 1572-1575. (Pubitemid 36836682)
31. Cooke, J. P. (2004). Asymmetrical dimethylarginine: the uber marker? Circulation, 109(15), 1813-1818.
32. Suda, O., Tsutsui, M., Morishita, T., Tasaki, H., Ueno, S., Nakata, S., et al. (2004). Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1682-1688. (Pubitemid 39180895)
33. Natale, A., Pisanó, E., Beheiry, S., Richey, M., Leonelli, F., Fanelli, R., et al. (2000). Ablation of right and left atrial premature beats following cardioversion in patients with chronic atrial fibrillation refractory to antiarrhythmic drugs. The American Journal of Cardiology, 1, 85(11), 1372-1375. (Pubitemid 30314676)
34. Schmitt, C., Ndrepepa, G., Weber, S., Schmieder, S., Weyerbrock, S., Schneider, M., et al. (2002). Biatrial multisite mapping of atrial premature complexes triggering onset of atrial fibrillation. The American Journal of Cardiology, 15, 89(12), 1381-1387. (Pubitemid 34607778)
35. Lin, W. S., Tai, C. T., Hsieh, M. H., Tsai, C. F., Lin, Y. K., Tsao, H. M., et al. (2003). Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. Circulation, 1, 107(25), 3176-3183.
36. Stühlinger, M. (2007). Asymmetric dimethylarginine (ADMA) : a novel cardiovascular risk factor? Wiener Medizinische Wochenschrift, 157 (3-4), 57-60. (Pubitemid 46622594)
37. Szuba, A., & Podgorski, M. (2006). Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor-evidence from epidemiological and prospective clinical trials. Pharmacological Reports, 58 Suppl, 16-20.
38. Allessie, M. A., Boyden, P. A., Camm, A. J., Kleber, A. G., Lab, M. J., Legato, M. J., et al. (2001). Pathophysiology and prevention of atrial fibrillation. Circulation, 103(5), 769-777. (Pubitemid 32144209)
39. Engelmann, M. D., & Svendsen, J. H. (2005). Inflammation in the genesis and perpetuation of atrial fibrillation. European Heart Journal, 26, 2083-2092. (Pubitemid 41408600)
40. Boos, C. J., Anderson, R. A., & Lip, G. Y. (2006). Is atrial fibrillation an inflammatory disorder? European Heart Journal, 27, 136-149. (Pubitemid 43069029)
41. Kurotobi, T., Iwakura, K., Inoue, K., Kimura, R., Okamura, A., Koyama, Y., et al. (2010). A pre-existent elevated C-reactive protein is associated with the recurrence of atrial tachyarrhythmias after catheter ablation in patients with atrial fibrillation. Europace, 12(9), 1213-1218.
42. Osmancik, P., Peroutka, Z., Budera, P., Herman, D., Stros, P., & Straka, Z. (2010). Changes in cytokine concentrations following successful ablation of atrial fibrillation. European Cytokine Network, 1, 21(4), 278-284.
43. Luan, Y., Guo, Y., Li, S., Yu, B., Zhu, S., Li, S., et al. (2010). Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Europace, 12(12), 1713-1718.
44. Degener, S., Pattberg, S. V., Feuersenger, H., Bansmann, P. M., Shin, D. I., Krummenauer, F., et al. (2007). Plasma natriuretic peptide concentrations as a predictor for successful catheter ablation in patients with drug-refractory atrial fibrillation. Circulation Journal, 71(3), 313-320.
45. Shimano, M., Shibata, R., Inden, Y., Yoshida, N., Uchikawa, T., Tsuji, Y., et al. (2009). Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. Heart Rhythm, 6(7), 935-940.